Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Resiniferatoxin - Sorrento Therapeutics

Next Previous
Drug Profile

Resiniferatoxin - Sorrento Therapeutics

Alternative Names: MCP 101; RTX

Latest Information Update: 11 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer ICOS Corporation; Mt Cook Pharma; National Institutes of Health (USA); Sorrento Therapeutics
  • Class Acetates; Analgesics; Anti-inflammatories; Azulenes; Non-opioid analgesics; Phenols; Phenyl ethers; Small molecules
  • Mechanism of Action TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cancer pain
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain
  • Phase I/II Cancer pain
  • Discontinued Interstitial cystitis; Overactive bladder; Rhinitis

Most Recent Events

  • 08 Sep 2023 Efficacy and adverse events data from a phase IIa OAK trial in Pain released by Sorrento Therapeutics
  • 28 Apr 2023 Suspended - Phase-II for Cancer pain (Late-stage disease) in USA (Epidural)
  • 26 Sep 2022 Sorrento Therapeutics plans to conduct an end of phase II meeting with the FDA for the RTX program in Pain (osteoarthritis knee pain)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top